JP2013509441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013509441A5 JP2013509441A5 JP2012537154A JP2012537154A JP2013509441A5 JP 2013509441 A5 JP2013509441 A5 JP 2013509441A5 JP 2012537154 A JP2012537154 A JP 2012537154A JP 2012537154 A JP2012537154 A JP 2012537154A JP 2013509441 A5 JP2013509441 A5 JP 2013509441A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- administered
- ginarine
- dose
- consecutive days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims 42
- 239000000203 mixture Substances 0.000 claims 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 8
- 150000002148 esters Chemical class 0.000 claims 8
- 239000002207 metabolite Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 6
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 238000007912 intraperitoneal administration Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- -1 SP3 Proteins 0.000 claims 2
- 238000011374 additional therapy Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000007914 intraventricular administration Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 102100040006 Annexin A1 Human genes 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 102100023147 E3 ubiquitin-protein ligase MARCHF7 Human genes 0.000 claims 1
- 102100026671 F-actin-capping protein subunit alpha-1 Human genes 0.000 claims 1
- 101000959738 Homo sapiens Annexin A1 Proteins 0.000 claims 1
- 101000978673 Homo sapiens E3 ubiquitin-protein ligase MARCHF7 Proteins 0.000 claims 1
- 101000910965 Homo sapiens F-actin-capping protein subunit alpha-1 Proteins 0.000 claims 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 1
- 101000584499 Homo sapiens Polycomb protein SUZ12 Proteins 0.000 claims 1
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 claims 1
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 claims 1
- 101000657366 Homo sapiens Transcription initiation factor TFIID subunit 7 Proteins 0.000 claims 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 1
- 102100040406 Lysophosphatidic acid receptor 6 Human genes 0.000 claims 1
- 101710149751 Lysophosphatidic acid receptor 6 Proteins 0.000 claims 1
- 101710130510 PEST proteolytic signal-containing nuclear protein Proteins 0.000 claims 1
- 102100024312 PEST proteolytic signal-containing nuclear protein Human genes 0.000 claims 1
- 102100030702 Polycomb protein SUZ12 Human genes 0.000 claims 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 claims 1
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 claims 1
- 102100034748 Transcription initiation factor TFIID subunit 7 Human genes 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 230000008033 biological extinction Effects 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 238000009225 cognitive behavioral therapy Methods 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 238000009226 cognitive therapy Methods 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000003840 hydrochlorides Chemical class 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 claims 1
- 238000002610 neuroimaging Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001671 psychotherapy Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25692709P | 2009-10-30 | 2009-10-30 | |
| US61/256,927 | 2009-10-30 | ||
| US26546809P | 2009-12-01 | 2009-12-01 | |
| US61/265,468 | 2009-12-01 | ||
| PCT/US2010/054872 WO2011053876A1 (en) | 2009-10-30 | 2010-10-29 | The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013509441A JP2013509441A (ja) | 2013-03-14 |
| JP2013509441A5 true JP2013509441A5 (enExample) | 2013-12-19 |
Family
ID=43922604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537154A Pending JP2013509441A (ja) | 2009-10-30 | 2010-10-29 | 記憶／認知および不安障害の処置のためのｃｉ−９９４およびジナリンの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8563615B2 (enExample) |
| EP (1) | EP2493298A4 (enExample) |
| JP (1) | JP2013509441A (enExample) |
| CN (1) | CN102834002A (enExample) |
| AU (1) | AU2010313255B2 (enExample) |
| CA (1) | CA2779497A1 (enExample) |
| IN (1) | IN2012DN03807A (enExample) |
| NZ (1) | NZ599757A (enExample) |
| WO (1) | WO2011053876A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110009475A1 (en) * | 2007-07-13 | 2011-01-13 | Massachusetts Institute Of Technology | Methods for treating stress induced emotional disorders |
| US8263547B2 (en) | 2008-05-28 | 2012-09-11 | Massachusetts Institute Of Technology | DISC-1 pathway activators in the control of neurogenesis |
| WO2011053876A1 (en) * | 2009-10-30 | 2011-05-05 | Massachusetts Institute Of Technology | The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
| WO2012003413A1 (en) * | 2010-06-30 | 2012-01-05 | The Broad Institute, Inc. | Novel solid forms of tacedinaline |
| WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
| US8691875B2 (en) | 2011-07-01 | 2014-04-08 | Broad Institute, Inc. | Solid forms of tacedinaline |
| PT2734510T (pt) | 2011-07-22 | 2019-02-13 | Massachusetts Inst Technology | Ativadores de histona desacetilases de classe i (hdacs) e seus usos |
| EP2877444B1 (en) * | 2012-07-27 | 2020-09-02 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| WO2014046871A1 (en) * | 2012-09-04 | 2014-03-27 | Massachusetts Institute Of Technology | The use of gene expression profiling as a biomarker for assessing the efficacy of hdac inhibitor treatment in neurodegenerative conditions |
| US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
| CA3125731A1 (en) | 2018-01-12 | 2019-07-18 | KDAc Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
| GB202001023D0 (en) * | 2020-01-24 | 2020-03-11 | Univ Leicester | HDAC Degrader |
| CN112062826A (zh) * | 2020-06-01 | 2020-12-11 | 暨南大学 | 一种与中枢神经衰老相关的乙酰化修饰h2b蛋白标记分子及其应用 |
| WO2023034440A1 (en) * | 2021-09-01 | 2023-03-09 | Case Western Reserve University | Treatment of neurodegenerative diseases with hdac inhibitors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525727A (en) | 1982-05-18 | 1996-06-11 | University Of Florida | Brain-specific drug delivery |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5177064A (en) | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
| US6110697A (en) | 1995-09-20 | 2000-08-29 | Merck & Co., Inc. | Histone deacetylase as target for antiprotozoal agents |
| ATE361316T1 (de) | 1999-09-08 | 2007-05-15 | Sloan Kettering Inst Cancer | Kristallstruktur einer deacetylase und deren inhibitoren |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| KR20100035666A (ko) | 1999-11-23 | 2010-04-05 | 메틸진 인크. | 히스톤 디아세틸라제의 억제제 |
| JP2001149081A (ja) | 1999-11-29 | 2001-06-05 | Cyclex Co Ltd | 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法 |
| EP2292593A3 (en) | 2000-09-29 | 2011-05-25 | TopoTarget UK Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| US20060148743A1 (en) | 2001-05-18 | 2006-07-06 | Vasant Jadhav | RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA) |
| WO2002102323A2 (en) | 2001-06-14 | 2002-12-27 | Bristol-Myers Squibb Company | Novel human histone deacetylases |
| CA2465978C (en) | 2001-09-14 | 2015-04-07 | Soon Hyung Woo | Inhibitors of histone deacetylase |
| EP1443928B1 (en) | 2001-10-16 | 2011-07-27 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| AU2002361022A1 (en) | 2001-12-07 | 2003-06-17 | Novartis Ag | Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors |
| JP2005517007A (ja) | 2002-02-07 | 2005-06-09 | アクシス・ファーマスーティカルズ | ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート |
| WO2003066885A2 (en) | 2002-02-08 | 2003-08-14 | Novartis Ag | Method for screening for compounds having hdac inhibitory activity |
| US20050288227A1 (en) | 2002-02-15 | 2005-12-29 | Marks Paul A | Use of thioredoxin measurements for diagnostics and treatments |
| US20030235588A1 (en) * | 2002-02-15 | 2003-12-25 | Richon Victoria M. | Method of treating TRX mediated diseases |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| WO2003083067A2 (en) | 2002-03-28 | 2003-10-09 | Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
| US20030224473A1 (en) | 2002-05-23 | 2003-12-04 | Mccafferty Dewey G. | Methods for screening for histone deacetylase activity and for identifying histone deacetylase inhibitors |
| EP1551795A1 (en) | 2002-10-17 | 2005-07-13 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| TW200424174A (en) | 2003-02-06 | 2004-11-16 | Hoffmann La Roche | New TP diamide |
| US20050037992A1 (en) | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| AU2004276337B2 (en) | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US20050227929A1 (en) * | 2003-11-13 | 2005-10-13 | Masferrer Jaime L | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent |
| AU2005225471B2 (en) | 2004-03-26 | 2011-05-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| JP2007533745A (ja) * | 2004-04-20 | 2007-11-22 | アールエヌディー・ファーマシューティカルズ | 脂溶性のシリコン置換シクロオキシゲナーゼ−２選択的非ステロイド性抗炎症薬及び誘導体の医薬組成物及び使用方法 |
| EP1591109B1 (en) * | 2004-04-30 | 2008-07-02 | TopoTarget Germany AG | Formulation comprising histone deacetylase inhibitor exhibiting biphasic release |
| US20060008517A1 (en) | 2004-07-09 | 2006-01-12 | Lynch Marina A | Treatment of age-related memory impairment |
| US20060018921A1 (en) | 2004-07-16 | 2006-01-26 | Baylor College Of Medicine | Histone deacetylase inhibitors and cognitive applications |
| CA2587013A1 (en) | 2004-11-08 | 2006-05-18 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| JP2008540574A (ja) | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| US20070015183A1 (en) | 2005-06-03 | 2007-01-18 | The General Hospital Corporation | Biomarkers for huntington's disease |
| CA2615105A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2621560A1 (en) | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
| WO2007049262A1 (en) * | 2005-10-27 | 2007-05-03 | Berand Limited | Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders |
| JP2009514859A (ja) | 2005-11-03 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | 置換ニコチンアミド化合物 |
| WO2007056435A2 (en) * | 2005-11-08 | 2007-05-18 | The General Hospital Corporation | Dynamin mediated diseases and associated methods and products |
| US8168658B2 (en) | 2006-02-28 | 2012-05-01 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase |
| CA2648804C (en) | 2006-04-07 | 2014-05-27 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
| WO2007127137A2 (en) | 2006-04-26 | 2007-11-08 | Merck & Co., Inc. | Disubstituted aniline compounds |
| CA2651681A1 (en) | 2006-05-18 | 2007-11-29 | Merck & Co., Inc. | Aryl-fused spirocyclic compounds |
| US20100112600A1 (en) | 2006-07-13 | 2010-05-06 | Azard Bonni | Methods and compositions for modulating synapse formation |
| US8088951B2 (en) | 2006-11-30 | 2012-01-03 | Massachusetts Institute Of Technology | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss |
| US8030344B2 (en) | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US20110009475A1 (en) | 2007-07-13 | 2011-01-13 | Massachusetts Institute Of Technology | Methods for treating stress induced emotional disorders |
| US8263547B2 (en) | 2008-05-28 | 2012-09-11 | Massachusetts Institute Of Technology | DISC-1 pathway activators in the control of neurogenesis |
| AU2009274571A1 (en) | 2008-07-23 | 2010-01-28 | Massachusetts Institute Of Technology | Activation of histone deacetylase 1 (HDAC1) protects against DNA damage and increases neuronal survival |
| JP2012510512A (ja) | 2008-12-03 | 2012-05-10 | マサチューセッツ インスティテュート オブ テクノロジー | 記憶を推進するためのｈｄａｃ２の阻害 |
| WO2010098888A1 (en) | 2009-02-27 | 2010-09-02 | Massachusetts Institute Of Technology | Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders |
| WO2011053876A1 (en) | 2009-10-30 | 2011-05-05 | Massachusetts Institute Of Technology | The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
| PT2734510T (pt) | 2011-07-22 | 2019-02-13 | Massachusetts Inst Technology | Ativadores de histona desacetilases de classe i (hdacs) e seus usos |
-
2010
- 2010-10-29 WO PCT/US2010/054872 patent/WO2011053876A1/en not_active Ceased
- 2010-10-29 CN CN201080060203XA patent/CN102834002A/zh active Pending
- 2010-10-29 CA CA2779497A patent/CA2779497A1/en not_active Abandoned
- 2010-10-29 AU AU2010313255A patent/AU2010313255B2/en not_active Ceased
- 2010-10-29 IN IN3807DEN2012 patent/IN2012DN03807A/en unknown
- 2010-10-29 EP EP10827583.5A patent/EP2493298A4/en not_active Withdrawn
- 2010-10-29 NZ NZ599757A patent/NZ599757A/en not_active IP Right Cessation
- 2010-10-29 JP JP2012537154A patent/JP2013509441A/ja active Pending
- 2010-11-01 US US12/917,402 patent/US8563615B2/en not_active Expired - Fee Related
-
2012
- 2012-08-27 US US13/595,048 patent/US8841346B2/en active Active